Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
300 articles
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A completed Canadian platform trial enrolls 354 at-risk adults in a multidomain online brain health program targeting dementia prevention.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A new study warns that diabetes medications could confound Alzheimer's biomarker studies, distorting our understanding of the diabetes-dementia link.
A formal erratum updates a 2026 cross-sectional survey on mental health factors affecting early-career dementia researchers worldwide.
A key potassium channel, KCNA4, is lost in vulnerable brainstem neurons at Braak II — potentially fueling tau pathology progression.
New research links somatic DNA variants in microglia-like cells to Alzheimer's pathology, opening a novel genetic avenue for disease intervention.
A major Nature Reviews Nephrology analysis reveals uremic toxins, BBB breakdown, and glymphatic failure drive cognitive decline in CKD patients.
New review reveals how glymphatic and meningeal lymphatic dysfunction drive Aβ and tau buildup, and how sleep, surgery, and genetics factor in.
Deleting or inhibiting astrocytic PERK restores the brain's glymphatic drainage system and dramatically reduces Aβ and tau pathology in AD mouse models.
A major meta-analysis reveals DLB incidence rises steeply with age and is higher in men, but widespread underdiagnosis distorts true burden.
A 25-year review of 577 AD vaccine formulations finds only 3 have targeted both Aβ and tau — a major missed opportunity.
